Shire on the hunt for right-size deals; AbbVie wins FDA nod for another hep C combo;

@FierceBiotech: Biogen targets new biotech deals after reporting sour numbers, R&D setbacks. More | Follow @FierceBiotech

@JohnCFierce: These days, when the FDA locks the door to a cancer drug, it's saying something -- $SNSS. Release | Follow @JohnCFierce

> Shire ($SHPG), like many drugmakers, has had to pump the brakes on its M&A ambitions in response to rising valuations, but CEO Flemming Ornskov said the company is prepared to wait for the right opportunity. News

> The FDA approved AbbVie's ($ABBV) Technivie, which contains the same active ingredients as the hepatitis C cocktail Viekira Pak, to treat patients with genotype 4 of the virus. More

> Roche's ($RHHBY) to move into Phase III with AC Immune's in-development Alzheimer's treatment paves the way for the Swiss biotech to go public, according to its CEO. Story

Medical Device News

@FierceMedDev: ICYMI yesterday: Bard hit with FDA warning letter affecting its vena cava filters. Article | Follow @FierceMedDev

@VarunSaxena2: ICYMI yesterday: Stroke-fighting Watchman, SpyGlass endoscope fuel strong Q2 for Boston Sci. Article | Follow @VarunSaxena2

@EmilyWFierce: Spotlight-savvy Kim Kardashian adds Duchesnay med to her talking points. More from FiercePharmaMarketing | Follow @EmilyWFierce

> Wall Street not anticipating another suitor for Thoratec on heels of St. Jude's $3.4B bid. Story

> Stryker: M&A still top priority for cash, but spent only $92M in first half on acquisitions. More

> ViewRay goes public via reverse merger, raises almost $77M since IPO cancellation. Article

> Oxford Performance Materials gets FDA nod for 3-D printed spinal implant. Report

Pharma News

@FiercePharma: India's drug and CRO manufacturing travails gather pace as New Delhi calls on diplomats to help. FiercePharmaAsia story | Follow @FiercePharma

@EricPFierce: Two Sandoz plants in Germany and 1 in India to be shuttered by Novartis next year. FiercePharmaManufacturing story | Follow @EricPFierce

@CarlyHFierce: ICYMI yesterday: Forecast-beating Valeant ups 2015 guidance with fast-growing Xifaxan in mind. Story | Follow @CarlyHFierce

> Biogen gets beaten up as slowing Tecfidera sales lead it to trim forecast. More

> Shire CEO: We're prepared to wait for the right deal. Story

Suggested Articles

Xevinapant in combination with standard cisplatin-based chemoradiation therapy (CRT) reduces the risk of death in high-risk patients with locally adva

Ironwood had once hyped this drug as a $2 billion-a-year asset, but IW-3718 has failed to live up to its high expectations.

Junshi’s PD-1 blocker is already approved in China for metastatic melanoma, but the Shanghai-based biotech may soon add throat cancer to its label.